The one memory gain faded, and no one has run the trial again
A panel with nothing to sell reviewed lion's mane in 2024. It found plausible cell and animal work, and one very small human trial whose gain faded and nobody repeated.
What the study found
The memory result was temporary, and nobody has repeated it
A panel that reviews alternative treatments for motor neurone disease, with nothing to sell, assessed lion's mane in 2024. It found plausible mechanisms in cells and animals, one very small human trial whose gain faded and which nobody had repeated, and no data at all on the disease.
The caveat · Judged for one disease, not memory
This panel carries no new data of its own and was answering a narrow question about one disease, so its refusal to recommend lion's mane there is not a verdict on memory claims in general. What does travel is its flat report that the memory finding stands unrepeated.